PeptideDB

EB1 42951-68-8

EB1 42951-68-8

CAS No.: 42951-68-8

EB1 is an inhibitor (blocker/antagonist) of MNK kinase with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

EB1 is an inhibitor (blocker/antagonist) of MNK kinase with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively suppresses the growth of cancer cells and does not suppress the growth of normal cells. EB1 also increases apoptosis and inhibits eIF4E phosphorylation.

Physicochemical Properties


Molecular Formula C18H14N4
Molecular Weight 286.33
Exact Mass 286.122
Elemental Analysis C, 75.50; H, 4.93; N, 19.57
CAS # 42951-68-8
PubChem CID 2048804
Appearance Light yellow to yellow solid powder
LogP 4.455
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 3
Rotatable Bond Count 2
Heavy Atom Count 22
Complexity 362
Defined Atom Stereocenter Count 0
SMILES

C1(C2=CC(C3=CC=CC=C3)=NC3=NNC(N)=C23)=CC=CC=C1

InChi Key NGNHXYCLUMQSKR-UHFFFAOYSA-N
InChi Code

InChI=1S/C18H14N4/c19-17-16-14(12-7-3-1-4-8-12)11-15(20-18(16)22-21-17)13-9-5-2-6-10-13/h1-11H,(H3,19,20,21,22)
Chemical Name

4,6-Diphenyl-2H-pyrazolo[3,4-b]pyridin-3-amine
Synonyms

E-B1, E-B-1
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets MNK1 0.69 μM (IC50) MNK2 9.4 μM (IC50) eIF4E
ln Vitro EB1 (1.3–40 μM; 24 hours) suppresses eIF4E phosphorylation in a dose-dependent manner [1]. EB1 (2.5–40 μM; 72 hours) causes tumor cells to undergo apoptosis and exhibits dose-dependent cytotoxicity [1]. After acting on MNK kinase for 24 hours at concentrations of 5 μM, 10 μM, and 20 μM, EB1 does not interfere with the activation of upstream signals, such as p38 (p-p38) activation or the phosphorylation of its downstream effector HSP27 [1]. Compound 14 (EB1) has an inhibitory concentration of 0.74 μM and 5.18 μM on HepG2 and MCF-7 cancer cells, respectively[2].
Cell Assay Western Blot Analysis[1]
Cell Types: MDA-MB-231, MDA-MB-468, MCF7, and IMR90 cells
Tested Concentrations: 1.3 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Duration: 24 hrs (hours)
Experimental Results: Blocked the phosphorylation of eIF4E in a dose-dependent manner.

Apoptosis Analysis[1]
Cell Types: MDA-MB-231, MDA -MB-468, MCF7, and IMR90 cells
Tested Concentrations: 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Duration: 72 hrs (hours)
Experimental Results: Increased the percentage of apoptosis cells among tumor cells.
References

[1]. Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor. J Med Chem. 2022 Apr 28;65(8):6070-6087.

[2]. Nicotinonitrile-derived apoptotic inducers: Design, synthesis, X-ray crystal structure and Pim kinase inhibition. Bioorg Chem. 2022 Dec;129:106126.


Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.4925 mL 17.4624 mL 34.9247 mL
5 mM 0.6985 mL 3.4925 mL 6.9849 mL
10 mM 0.3492 mL 1.7462 mL 3.4925 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.